Datapoint: FDA Approves TG Therapeutics’ Ukoniq

The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data suggests it may be safer than its rival PI3K inhibitors, including Gilead Sciences’ Zydelig and Bayer’s Aliqopa, and the FDA will not require a black box warning on the new drug. For the treatment of marginal zone lymphoma, Zydelig currently holds preferred formulary placement for 17% of covered lives, compared to Aliqopa’s 4%.

SOURCE: MMIT Analytics, as of 2/10/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 27

Datapoint: FDA Approves First Interchangeable Humira Biosimilar

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today